Self-amplifying RNA technology applied to the development of a universal influenza vaccine

Project Information

SAMUFLU

Grant agreement ID: 626283

Project closed

Start date 1 April 2014

End date 31 March 2016

Funded under

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Total cost € 187 414,80

EU contribution € 187 414,80

Coordinated by

GLAXOSMITHKLINE VACCINES SRL
Italy